Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models

Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models

Volumn 9780470582299, Issue , 2014, Pages 1-301

  Owen, Joel S ^a   Fiedler Kelly, Jill ^b,c  

^a UNION UNIVERSITY   (United States)

^b Albany Medical College   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAYESIAN NETWORKS; CONTROLLED DRUG DELIVERY; MODEL BUILDINGS; NONLINEAR ANALYSIS; PHARMACOKINETICS;

DATA REQUIREMENTS; EMPIRICAL BAYESIAN; MODEL AND SIMULATION; MODEL APPLICATION; NONLINEAR MIXED EFFECTS; POPULATION PHARMACOKINETICS; PROGRAMMING CODES; QUALITY CONTROL ASPECTS;

QUALITY CONTROL;

EID: 84926121304     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118784860     Document Type: Book

References (120)

1. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 2nd ed. New York: Springer; 2011.
2. Ette EI, Williams PJ. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken: Wiley-Interscience; 2007.
3. FDA Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration. FDA Pharmacometrics 2020 Strategic Goals. Available at http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm167032.htm#FDAPharmacometrics2020StrategicGoals. Accessed July 11, 2013.
4. Gobburu JVS. Pharmacometrics 2020. J Clin Pharmacol 2010;50:151S-157S.
5. Sheiner LB, Benet LZ. Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther 1985;38 (5):481-487.
6. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. (1989-2011). Icon Development Solutions, Hanover, MD. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides. Accessed December 6, 2013.
7. BestDose, Laboratory of Applied Pharmacokinetics. 2000-2013. Laboratory of Applied Pharmacokinetics.
8. Bhattaram VA, Booth BP, Ramchandani RP, Beasley BN, Wang Y, Tandon V, Duan JZ, Baweja RK, Marroum PJ, Uppoor RS, Rahman NA, Sahajwalla CG, Powell JR, Mehta MU, Gobburu JVS. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7(3):E503-E512.
9. Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger HR, Cox SL, Inge TH, Knibbe CA, Vinks AA. Propofol clearance in morbidly obese children and adolescents. Clin Pharmacokinet 2012; 51(8):543-551.
10. FDA Briefing Document, NDA 200677, Pasireotide Injection: 600 mcg, 900 mcg, Endocrinologic and Metabolic Drugs, Advisory Committee Meeting, November 7, 2012. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM326811.pdf. Accessed January 22, 2013.
11. Food and Drug Administration, Guidance for Industry, Population Pharmacokinetics. Rockville: Food and Drug Administration; 1999.
12. Gobburu JVS. Pharmacometrics 2020. J Clin Pharmacol 2010; 50:151S-157S.
13. Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012; 52:119S-125S.
14. Knebel K, Bergsma T, Fisher J, Georgalis G, Gibiansky L, Gillespie B, Riggs M, Gastonguay MR. Facilitating the Pharmacometrics Work-Flow with the MItools R Package. Metrum Institute, Tariffville, CT. American Conference on Pharmacometrics, Tuscon, AZ, 2008. Available at http://metruminstitute.org. Accessed December 6, 2013.
15. Lee JY, Garnett CE, Gobburu JVS, Bhattaram VA, Brar S, Jadhav PR, Krudys K, Lesko LJ, Li F, Liu J, Madabushi R, Marathe A, Mehrotra N, Tomoe C, Wang Y, Zhu H. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008. Clin Pharmacokinet 2011; 50(10):627-635.
16. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75(2):85-94.
17. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79(3):241-257.
18. PLT Tools 2013, PLTSoft, PLT Tools, San Francisco, CA, 2006-2013. Available at http://www.pltsoft. com. Accessed December 6, 2013.
19. Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000;92 (3):727-738.
20. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters, I. Michelis-Menten model: routine clinical data. J Pharmacokinet Biopharm 1980; 8:553-571.
21. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9:635-651.
22. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters III. Monoexponential model and routine clinical data. J Pharmacokinet Biopharm 1983;11:303-319.
23. Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to the estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed effects model. Drug Metab Rev 1984;15:265-292.
24. Stone J, Banfield C, Pfister M, Tannenbaum S, Wetherington JD, Krishna R, Grasela DM. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol 2010; 50(1 Suppl):20S-30S.
25. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides (1989-2011). Icon Development Solutions, Hanover, MD; 2001. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides. Accessed December 13, 2013.
26. Gobburu JVS. Pharmacometrics 2020. J Clin Pharm 2010;50:151S-157S.
27. Petersson KJF, Hanze E, Savic RM, Karlsson MO. Semiparametric distributions with estimated shape parameters. Pharm Res 2009;26 (9):2174-2185.
28. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med 2008;59:1-12.
29. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. 1989 NONMEM 7.2.0 Users Guides (1989-2011). Icon Development Solutions, Hanover. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides. Accessed December 13, 2013.
30. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling And Simulation. New York: Springer Science + Business Media, LLC; 2006. p 65-69.
31. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58 (1):51-64.
32. R Core Team. R: A Language and Environment for Statistical Computing. 2013. R Foundation for Statistical Computing, Vienna. Available at http://www.R-project.org. Accessed December 13, 2013.
33. SAS Institute Inc., SAS User's Guides, Version 9, 1st ed., volumes 1-3. Cary: SAS Institute Inc.; 2008.
34. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. Hanover: Icon Development Solutions; 1989-2011.
35. R Development Core Team (2013). R: A Language and Environment for Statistical Computing. Vienna:R Foundation for Statistical Computing. Available at http://www.R-project.org/. Accessed December 16, 2013.
36. SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. Cary: SAS Institute Inc; 2002-2010.
37. Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008;35(4): 401-421. Erratum in: J Pharmacokinet Pharmacodyn 2010 Jun;37(3):305-308.
38. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009;24(1):25-36. Review.
39. Beal SL. Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2002;29 (4):403-412.
40. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001;28(5):481-504. Erratum in J Pharmacokinet Pharmacodyn 2002b;29(3):309.
41. Beal SL, Sheiner LB. Course Notes: A Short Course in Population Pharmacokinetic Data Analysis Using the NONMEM System. San Francisco: University of California at San Francisco; 1992.
42. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. Hanover: Icon Development Solutions; 1989-2011. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides. Accessed December 14, 2013.
43. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling And Simulation. New York: Springer Science + Business Media, LLC; 2006. p 65-69.
44. Byon W, Fletcher CV, Brundage RC. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 2008 Feb;35 (1):101-116.
45. Draper NR, Smith H. Applied Regression Analysis. 2nd ed. New York: John Wiley & Sons, Inc.; 1981a. p 16-17.
46. Draper NR, Smith H. Applied Regression Analysis. 2nd ed. New York: John Wiley & Sons, Inc.; 1981b. p 29-30.
47. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 2004;38:2136-2144.
48. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on Reporting the Results of Population Pharmacokinetic Analyses. 2007. Available at www.ema.europa. eu/pdfs/human/ewp/18599006enfin.pdf. Accessed December 14, 2013.
49. European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP) ICH E9: Statistical Principles for Clinical Trials. 1998. Available at www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf. Accessed December 14, 2013.
50. Food and Drug Administration, Guidance for Industry, Population Pharmacokinetics. Rockville: Food and Drug Administration; 1999.
51. Freund JE. Mathematical Statistics. 5th ed. Englewood: Prentice-Hall, Inc; 1992. p 442-448.
52. Gastonguay MR. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J 2004;6(S1). Available at www.aapsj.org/abstracts/AM_2004/AAPS2004-003431.PDF. Accessed December 14, 2013.
53. Gobburu JV, Lawrence J. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm Res 2002; 19 (1):92-98.
54. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007;24 (12):2187-2197.
55. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res 1998;15:1463-1468.
56. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58 (1):51-64.
57. Khandelwal A, Harling K, Jonsson EN, Hooker AC, Karlsson MO. A fast method for testing covariates in population PK/PD models. AAPS J 2011;13 (3):464-472.
58. Kowalski KG, Hutmacher MM. Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test. J Pharmacokinet Pharmacodyn 2001;28:253-275.
59. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79 (3):241-257.
60. Mandema JM, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models I. Models for covariate effects. J Pharmacokinet Biopharm 1992;20:511-528.
61. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna; 2013. Available at http://www.R-project.org. Accessed December 14, 2013.
62. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009;11:558-69.
63. S-Plus [computer program] Version 7. Seattle: Insightful Corporation; 2005.
64. Tukey JW. Exploratory Data Analysis. Reading: Addison-Wesley; 1977.
65. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 2001;28:231-252.
66. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. (1989-2011). Hanover: Icon Development Solutions.
67. Bonate PL. Pharmacokinetic-Pharmacodynamic Modeling And Simulation. New York: Springer Science + Business Media, LLC; 2006. p 65-69.
68. Neter J, Wasserman W, Kutner MH. Applied Linear Statistical Models: Regression, Analysis of Variance, and Experimental Designs. Homewood: Irwin, Inc; 1985. p 98-99.
69. Ashby D. Bayesian statistics in medicine: a 25 year review. Statis Med 2006;25:3589-3631.
70. Bayes T. An essay towards solving a problem in the doctrine of chances. Philos Trans R Soc Lond 1763;53:370-418.
71. Bourne D. Bayesian analysis of clinical data. In: Basic Pharmacokinetics. 2013. p 314.
72. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982;71 (12):1344-1348.
73. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011;13 (2):143-151.
74. Brendel K, Comets E, Laffont C, Laveille C, Mentré F. Metrics for evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 2006;23 (9):2036-2049.
75. Brendel K, Comets E, Laffont C, Mentré F. Evaluation of different tests based on observations for external model evaluation of population analyses. J Pharmacokinet Pharmacodyn 2010;37:49-65.
76. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008;90:154-166.
77. Food and Drug Administration (FDA), Guidance for Industry, Population Pharmacokinetics. Rockville:Food and Drug Administration; 1999.
78. Jadhav PR and Gobburu JVS, A new equivalence based metric for predictive check to qualify mixedeffects models. AAPS J 2005;7(3):E523-E531. Article 53.
79. Karlsson MO, Holford NH. A tutorial on visual predictive checks; 2008. PAGE 17. Abstr 1434. Available from www.page-meeting.org/?abstract=1434. Accessed December 16, 2013.
80. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007;82:17-20.
81. Lavielle M, Bleakley K. Automatic data binning for improved visual diagnosis of pharmacometric models. J Pharmacokinet Pharmacodyn 2011;38 (6):861-871.
82. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79 (3):241-257.
83. Mentré F, Escolano S. Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokinet Pharmacodyn 2006;33:345-367.
84. NPC/VPC user guide and technical description 2013 PsN 3.6.2. Available at http:\\psn.sourceforge.net/pdfdocs/vpc_npc_userguide.pdf. Accessed December 16, 2013.
85. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008;35:185-202.
86. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9 (4):503-12.
87. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm 1990;18:161-173.
88. Wang DD, Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation J Clin Pharmacol 2012;52(1):39-54. Erratum in J Clin Pharmacol 2012 Apr;52(4):NP1-NP3.
89. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001;28 (2):171-192.
90. Chatelut E, Rostaing L, Grégoire N, Payen J-L, Pujol A, Izopet J, Houin G, Canal P. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 1999;47:365-371.
91. Wade JR, Kelman AW, Howie CA, Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21 (2):209-222.
92. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. (1989-2011). Icon Development Solutions, Hanover. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides. Accessed December 13, 2013.
93. Ette EI, Williams PJ. Pharmacometrics: The Science of Quantitative Pharmacology. 2007. Wiley-Interscience. Hoboken, NJ.
94. Krzyzanski W, Jusko WJ. Mathematical formalism for the properties of four basic models of indirect pharmacodynamics responses. J Pharmacokinet Biopharm 1997; 25(1):107-123.
95. Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R. The clinical utility index as a practical multiattribute approach to drug development decisions. Clin Pharm Ther 2009; 86 (1):105-108.
96. Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH. Dose proportionality of cisatracurium. J Clin Pharmacol 1997; 37(7):625-629.
97. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharm Ther 1979; 25(3):358-371.
98. Wade J, Karlsson MO. Combining PK and PD data during population PK/PD analysis [Abstract ] 1999, PAGE 8. Abstr 139. Available at www.page-meeting.org/?abstract=139. Accessed August 31, 2013.
99. William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H. Quantification of disease progression and dropout for Alzheimer's disease. Int J Clin Pharmacol Therap 2013; 51(2):120-131.
100. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 2003; 30(6):387-404.
101. Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM 7.2.0 Users Guides. (1989-2011). Hanover: Icon Development Solutions. Available at ftp://nonmem.iconplc.com/Public/nonmem720/guides/. Accessed December 7, 2013.
102. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1):31-41.
103. Efron B. Bootstrap methods: another look at jackknife. Ann Statist 1979;7:1-26.
104. Food and Drug Administration (FDA), Guidance for Industry Population Pharmacokinetics. Food and Drug Administration: Rockville; 1999.
105. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Therap 2007;82:17-20.
106. Kimko HC, Duffull SB. Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective. New York: Informa Healthcare USA, Inc; 2007. p 1-130.
107. Poland B, Hodge FL, Khan A, Clemen RT, Wagner JA, Dykstra K, Krishna R. The clinical utility index as a practical multiattribute approach to drug development decisions. Clin Pharmacol Ther 2009; 86 (1):105-108.
108. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. Pharm Res 2008;25 (1):183-193.
109. Bonate PL, Strougo A, Desai A, Roy M, Yassen A, van der Walt JS, Kaibara A, Tannenbaum S. Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective. AAPS J 2012;14 (4):749-758.
110. Chowdhury S. Creating NONMEM datasets-how to escape the nightmare. Pharm Program 2010;3 (2):80-83.
111. Collins A, Peterson M, Silva G. Streamlining the PK/PD data transfer process. Pharm Program 2010;3 (1):24-28.
112. Collins A, Silva G. Streamlining the PK/PD data transfer process-1 year later. Pharm Program 2011;4 (1&2):28-30.
113. EMEA, Guideline on Reporting the Results of Population Pharmacokinetic Analyses, EMEA: London, 2007.
114. Food and Drug Administration, Guidance for Industry, Population Pharmacokinetics. Food and Drug Administration: Rockville; 1999.
115. Grasela TH, Antal EJ, Fiedler-Kelly J, Foit DJ, Barth B, Knuth DW, Carel BJ, Cox SR. An automated drug concentration screening and quality assurance program for clinical trials. Drug Info J 1999;33:273-279.
116. Grasela TH, Fiedler-Kelly J, Hitchcock DJ, Ludwig EA, Passarell JA. Forensic pharmacometrics: part 1-data assembly [abstract]. PAGE 19 (2010a) Abstr 1901. Available at www.page-meeting. org/?abstract=1901. Accessed December 14, 2013.
117. Grasela TH, Fiedler-Kelly J, Ludwig EA, Passarell JA, Hitchcock DJ. Forensic pharmacometrics: part 2-deliverables for regulatory submission [abstract]. PAGE 19 (2010b) Abstr 1902. Available at www. page-meeting.org/?abstract=1902. Accessed December 14, 2013.
118. Grasela TH, Ludwig E, Fiedler-Kelly J. Kerfuffle!. J Clin Pharmacol 2009;49 (4):386-388.
119. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption testing in population pharmacokinetic models:illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm 1998;26 (2):207-246.
120. Wade JR, Edholm M and Salmonson T. A guide for reporting the results of population pharmacokinetic analyses: a Swedish perspective. AAPS J 2005;7(2):E456-E460. Article 45.